Pulmatrix and Cullgen Merger: A Deep Dive into the Future of Inhaled Therapeutics

Overview of Pulmatrix, Inc.

Pulmatrix, Inc., a biopharmaceutical company based in Framingham, Massachusetts, is carving out a niche in the medical field by developing innovative inhaled therapeutic products. Their main focus lies in addressing conditions like migraines and respiratory diseases using their proprietary iSPERSE technology. This cutting-edge approach promises not only effective drug delivery to the lungs but also aims to tackle significant unmet medical needs.

Proposed Merger with Cullgen

On November 13, 2024, Pulmatrix announced an agreement to merge with Cullgen Inc., a clinical-stage biopharmaceutical company specializing in targeted protein degraders for treating pain, cancer, and other health issues. This merger is set to align two companies with a common goal: advancing therapeutic solutions and optimizing drug delivery.

Current Status of the Merger

As of August 6, 2025, the merger is poised for completion in 2025, with some regulatory approvals pending. The U.S. Securities and Exchange Commission declared Pulmatrix’s registration statement effective, and shareholders approved the merger. However, the transaction is still subject to further conditions, including approval from Nasdaq and the China Securities Regulatory Commission.

Future Implications of the Merger

If the merger proceeds as planned, it will create a Nasdaq-listed entity that concentrates on advanced protein degradation technology. The combined company will boast three degrader programs currently in Phase 1 clinical trials—two targeting cancer and one aimed at acute and chronic pain treatments.

The Innovative iSPERSE Technology

Pulmatrix’s flagship innovation, the iSPERSE technology, represents a revolutionary leap in drug delivery systems. This technology allows for the formulation of small, dense, and dispersible particles that can effectively deliver medications deep into the lungs.

Advantages of iSPERSE

• Enhanced Delivery: The iSPERSE particles surpass traditional dry powder particles in terms of drug dispersibility, allowing for improved therapeutic outcomes compared to common oral and injectable solutions.
• Patent Portfolio: As of June 30, 2025, Pulmatrix holds approximately 146 granted patents for iSPERSE, which underscores the technology’s uniqueness and potential in the pharmaceutical arena.

Pulmatrix’s Product Pipeline

In addition to their groundbreaking technology, Pulmatrix is advancing a suite of clinical assets designed to treat a variety of conditions.

1. PUR3100

• Description: An orally inhaled formulation of dihydroergotamine engineered for acute migraine treatment.
• Clinical Status: The FDA has accepted a New Drug Application (IND) for PUR3100, allowing the initiation of a Phase 2 clinical study aimed at evaluating its safety and efficacy in patients suffering from acute migraines.

2. PUR1800

• Description: A narrow spectrum kinase inhibitor designed to combat acute exacerbations in chronic obstructive pulmonary disease (COPD).
• Clinical Results: The Phase 1b study results presented in 2023 showed that PUR1800 was safe and well-tolerated, paving the way for its further development in respiratory diseases.

3. PUR1900

• Description: An inhaled formulation of itraconazole, targeting unmet medical needs within the antifungal drug market.
• Development Status: With the completion of Phase 2 activities, Pulmatrix is leveraging partnerships, such as with Cipla, which is pursuing further clinical development for PUR1900 outside the United States.

Financial Performance Overview

In the second quarter of 2025, Pulmatrix reported a reduction in revenue, with figures dropping to $0 from $1.6 million in the same period in 2024. The decline was primarily attributed to the conclusion of the PUR1900 Phase 2b trial.

Research and Development Expenses

Research and development expenditures also saw a sharp decrease, plummeting to less than $100,000, reflecting the winding down of the PUR1900 program and associated operational restructures.

Cash Position

As of June 30, 2025, Pulmatrix maintained a cash and cash equivalents balance of $5.8 million, which the company anticipates will support operations at least until the contemplated merger with Cullgen concludes.

Conclusion

While the current focus centers on the impending merger and the innovative technology underpinning Pulmatrix’s drug delivery systems, the future holds significant promise. The combination of advanced inhaled therapeutics with targeted protein degradation strategies may redefine benchmarks for treatment in both preventive and therapeutic healthcare models. As the industry watches these developments unfold, Pulmatrix’s commitment to transforming how we approach both respiratory and CNS disorders stands as a pivotal aspect of its journey forward.